Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Depomed and Rottapharm|Madaus have announced that the Medical Products Agency in Sweden has issued the marketing authorization for ProQuin XR.
Subscribe to our email newsletter
Depomed’s ProQuin XR is exclusively licensed to Rottapharm|Madaus for Europe and is a once-daily extended-release formulation of ciprofloxacin hydrochloride for the treatment of uncomplicated urinary tract infections.
Antonino Santoro, corporate business development and regulatory affairs director of Rottapharm|Madaus, said: “ProQuin XR complements our product portfolio and strengthens our position in urology. ProQuin XR’s approval in Sweden paves the way for further regulatory approvals in other European countries through the mutual recognition procedure.
“We expect to launch the product under the trade-mark Utiminx starting in 2009 in different countries and in some of them we are planning to co-market the product under the secondary trade-mark Uritent.”